Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response

Abstract

The present disclosure teaches the use of a dual-acting opioid agonist for the treatment of pain (e.g., inflammatory pain). The opioid agonist activates both the kappa and delta opioid receptors to provide synergistic reduction in pain. The opioid agonist is peripherally restricted and does not cross the blood-brain barrier.

1 . A method of treating pain caused by inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 1: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof. 
     
     
         2 . The method of  claim 1 , wherein the pain is caused by initiation of the inflammatory response. 
     
     
         3 . The method of  claim 1 , wherein the pain is associated with hyperalgesia. 
     
     
         4 . The method of  claim 1 , wherein the pain is chronic pain or subacute pain. 
     
     
         5 . The method of  claim 1 , wherein the chronic pain is arthritis pain, low back pain, neuropathic pain, visceral pain, pain due to cancer, pain due to injury, pain due to joint inflammation, pain due to back disorders, or neck pain. 
     
     
         6 . The method of  claim 5 , wherein the pain due to cancer is caused by cancer involving intraperitoneal abdominal and pelvic organs or bone cancer or bone metastases. 
     
     
         7 . The method of  claim 5 , wherein the pain due to injury is caused by bone, ligament, or tendon injury. 
     
     
         8 . The method of  claim 1 , wherein Compound 1 reduces pain to a similar degree as a central-nervous system-acting opioid. 
     
     
         9 . The method of  claim 8 , wherein the central-nervous system-acting opioid activates a mu receptor. 
     
     
         10 . The method of  claim 8 , wherein the central-nervous system-acting opioid is morphine. 
     
     
         11 . The method of  claim 1 , wherein administrating Compound 1 does not result in any central-nervous system side effects. 
     
     
         12 . The method of  claim 11 , wherein the central nervous system side-effects are addiction, constipation, sedation, impaired mentation, somnolence, respiratory depression, nausea, dysphoria, or seizures. 
     
     
         13 . The method of  claim 12 , wherein administering Compound 1 does not result in constipation. 
     
     
         14 . The method of  claim 12 , wherein administrating Compound 1 does not result in addiction. 
     
     
         15 . The method of  claim 1 , wherein Compound 1 results in synergistic activation of kappa and delta opioid receptors. 
     
     
         16 . The method of  claim 16 , wherein the synergy results from allosteric modulation of kappa receptors by delta receptor activity. 
     
     
         17 . The method of  claim 1 , wherein administration of Compound 1 is similar or superior to a kappa receptor agonist for treatment of acute pain. 
     
     
         18 . The method of  claim 1 , wherein administration of Compound 1 is similar or superior to a kappa receptor agonist for treatment of hyperalgesia. 
     
     
         19 .- 24 . (canceled) 
     
     
         25 . A pharmaceutical composition comprising Compound 1: 
       
         
           
           
               
               
           
         
       
       and a pharmaceutically acceptable carrier.